# Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

> **NCT06270433** · NA · UNKNOWN · sponsor: **Jiangsu Province Nanjing Brain Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Anhedonia

## Interventions

- **DRUG:** Toludesvenlafaxine hydrochloride sustained-release tablets
- **DRUG:** Desvenlafaxine succinate sustained-release tablets

## Key facts

- **NCT ID:** NCT06270433
- **Lead sponsor:** Jiangsu Province Nanjing Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270433, "Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06270433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*